S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Solid Biosciences Stock Forecast, Price & News

0.00 (0.00%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
352,521 shs
Average Volume
944,077 shs
Market Capitalization
$71.12 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SLDB Stock Forecast (MarketRank)

Overall MarketRank

2.49 out of 5 stars

Medical Sector

144th out of 1,432 stocks

Biological Products, Except Diagnostic Industry

25th out of 217 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
Solid Biosciences logo

About Solid Biosciences (NASDAQ:SLDB)

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

SLDB Stock News Headlines

Solid Biosciences (NASDAQ:SLDB) Trading Down 7.2%
What 4 Analyst Ratings Have To Say About Solid Biosciences
Duchenne startup lays off 35% of staff, loses COO
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-72.19 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$13.62 million
Book Value
$1.89 per share


Free Float
Market Cap
$71.12 million

Solid Biosciences Frequently Asked Questions

Should I buy or sell Solid Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Solid Biosciences stock.
View analyst ratings for Solid Biosciences
or view top-rated stocks.

What is Solid Biosciences' stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price targets for Solid Biosciences' shares. Their SLDB stock forecasts range from $2.00 to $7.00. On average, they expect Solid Biosciences' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 613.8% from the stock's current price.
View analysts' price targets for Solid Biosciences
or view top-rated stocks among Wall Street analysts.

How has Solid Biosciences' stock price performed in 2022?

Solid Biosciences' stock was trading at $1.75 at the start of the year. Since then, SLDB stock has decreased by 64.0% and is now trading at $0.6304.
View the best growth stocks for 2022 here

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Solid Biosciences

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) announced its earnings results on Wednesday, April, 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $1.93 million for the quarter, compared to analyst estimates of $3.57 million. Solid Biosciences had a negative net margin of 660.25% and a negative trailing twelve-month return on equity of 37.71%. During the same quarter in the prior year, the company earned ($0.19) earnings per share.
View Solid Biosciences' earnings history

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the following people:
  • Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPA, Exec. Chair (Age 56, Pay $72.73k)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 48, Pay $749.03k)
  • Mr. Matthew Bennett Arnold, Co-Founder & Board Member (Age 52, Pay $19.45k)
  • Ms. Erin Powers Brennan, Chief Legal Officer & Sec. (Age 51, Pay $495.99k)
  • Mr. Gilad David Hayeem, Co-Founder (Age 54)
  • Ms. Annie Ganot, Co-Founder & Head of Patient Advocacy
  • Dr. Andrey Juan Zarur Ph.D., Co-Founder (Age 51)
  • Mr. Stephen J. Di Palma M.B.A, M.B.A., Interim CFO, Treasurer & Principal Accounting Officer (Age 63)
  • Dr. Carl Ashley Morris Ph.D., Chief Scientific Officer (Age 52) (LinkedIn Profile)
  • Ms. Caitlin Lowie, VP of Communications & IR

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $0.63.

How much money does Solid Biosciences make?

Solid Biosciences (NASDAQ:SLDB) has a market capitalization of $71.12 million and generates $13.62 million in revenue each year. The company earns $-72.19 million in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Solid Biosciences have?

Solid Biosciences employs 104 workers across the globe.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The official website for Solid Biosciences is www.solidbio.com. The company can be reached via phone at (617) 337-4680.

This page (NASDAQ:SLDB) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.